Quality of Life in Patients With Metastatic Prostate Cancer Following Treatment With Cabazitaxel vs Abiraterone or Enzalutamide
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Quality of Life in Patients With Metastatic Prostate Cancer Following Treatment With Cabazitaxel Versus Abiraterone or Enzalutamide (CARD): An Analysis of a Randomised, Multicentre, Open-Label, Phase 4 Study
Lancet Oncol 2020 Sep 11;[EPub Ahead of Print], K Fizazi, G Kramer, JC Eymard, CN Sternberg, J de Bono, D Castellano, B Tombal, C Wülfing, M Liontos, J Carles, R Iacovelli, B Melichar, Á Sverrisdóttir, C Theodore, S Feyerabend, C Helissey, S Oudard, G Facchini, EM Poole, A Ozatilgan, C Geffriaud-Ricouard, S Bensfia, R de WitFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.